• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

定量预测药物粉末气溶胶肺部沉积分布的方法。

A quantitative approach to predicting lung deposition profiles of pharmaceutical powder aerosols.

机构信息

Faculty of Pharmacy and Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.

Advanced Drug Delivery Group, School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.

出版信息

Int J Pharm. 2021 Jun 1;602:120568. doi: 10.1016/j.ijpharm.2021.120568. Epub 2021 Apr 2.

DOI:10.1016/j.ijpharm.2021.120568
PMID:33812969
Abstract

Dry powder inhalers (DPI) are widely used systems for pulmonary delivery of therapeutics. The inhalation performance of DPIs is influenced by formulation features, inhaler device and inhalation pattern. The current review presents the affecting factors with great focus on powder characteristics which include particle size, shape, surface, density, hygroscopicity and crystallinity. The properties of a formulation are greatly influenced by a number of physicochemical factors of drug and added excipients. Since available particle engineering techniques result in particles with a set of modifications, it is difficult to distinguish the effect of an individual feature on powder deposition behavior. This necessitates developing a predictive model capable of describing all influential factors on dry powder inhaler delivery. Therefore, in the current study, a model was constructed to correlate the inhaler device properties, inhalation flow rate, particle characteristics and drug/excipient physicochemical properties with the resultant fine particle fraction. The r value of established correlation was 0.74 indicating 86% variability in FPF values is explained by the model with the mean absolute errors of 0.22 for the predicted values. The authors believe that this model is capable of predicting the lung deposition pattern of a formulation with an acceptable precision when the type of inhaler device, inhalation flow rate, physicochemical behavior of active and inactive ingredients and the particle characteristics of DPI formulations are considered.

摘要

干粉吸入器(DPI)广泛用于肺部给药治疗。DPI 的吸入性能受制剂特征、吸入器装置和吸入方式的影响。目前的综述重点介绍了影响干粉吸入器输送的因素,其中包括粉末特性,如粒径、形状、表面、密度、吸湿性和结晶度。制剂的性质受药物和添加赋形剂的许多物理化学因素的极大影响。由于现有的颗粒工程技术会导致颗粒具有一系列的修饰,因此很难区分单个特征对粉末沉积行为的影响。这就需要开发一种能够描述干粉吸入器输送所有影响因素的预测模型。因此,在目前的研究中,建立了一个模型来关联吸入器装置特性、吸入气流率、颗粒特性以及药物/赋形剂的物理化学特性与细颗粒分数(FPF)的关系。建立的相关性的 r 值为 0.74,表明模型可以解释 86%的 FPF 值的变化,预测值的平均绝对误差为 0.22。作者认为,当考虑吸入器装置类型、吸入气流率、活性和非活性成分的物理化学行为以及干粉吸入制剂的颗粒特性时,该模型能够以可接受的精度预测制剂的肺部沉积模式。

相似文献

1
A quantitative approach to predicting lung deposition profiles of pharmaceutical powder aerosols.定量预测药物粉末气溶胶肺部沉积分布的方法。
Int J Pharm. 2021 Jun 1;602:120568. doi: 10.1016/j.ijpharm.2021.120568. Epub 2021 Apr 2.
2
The clinical relevance of dry powder inhaler performance for drug delivery.干粉吸入器用于药物递送的性能的临床相关性。
Respir Med. 2014 Aug;108(8):1195-203. doi: 10.1016/j.rmed.2014.05.009. Epub 2014 May 24.
3
Development of drug alone and carrier-based GLP-1 dry powder inhaler formulations.单独药物和基于载体的 GLP-1 干粉吸入剂制剂的开发。
Int J Pharm. 2022 Apr 5;617:121601. doi: 10.1016/j.ijpharm.2022.121601. Epub 2022 Feb 16.
4
Computationally efficient analysis of particle transport and deposition in a human whole-lung-airway model. Part II: Dry powder inhaler application.人体全肺气道模型中颗粒传输与沉积的高效计算分析。第二部分:干粉吸入器应用。
Comput Biol Med. 2017 May 1;84:247-253. doi: 10.1016/j.compbiomed.2016.10.025. Epub 2016 Nov 3.
5
Enhancement of the extra-fine particle fraction of levofloxacin embedded in excipient matrix formulations for dry powder inhaler using response surface methodology.使用响应面法提高用于干粉吸入器的赋形剂基质制剂中左氧氟沙星的超细颗粒部分
Eur J Pharm Sci. 2021 Jan 1;156:105600. doi: 10.1016/j.ejps.2020.105600. Epub 2020 Oct 17.
6
Exploring the potential influence of drug charge on downstream deposition behaviour of DPI powders.探讨药物电荷对 DPI 粉末下游沉积行为的潜在影响。
Int J Pharm. 2020 Oct 15;588:119798. doi: 10.1016/j.ijpharm.2020.119798. Epub 2020 Aug 21.
7
Elucidation of lactose fine size and drug shape on rheological properties and aerodynamic behavior of dry powders for inhalation.阐明乳糖的细微颗粒大小和药物形状对吸入干粉的流变性能和空气动力学行为的影响。
Eur J Pharm Biopharm. 2022 Oct;179:47-57. doi: 10.1016/j.ejpb.2022.08.007. Epub 2022 Aug 25.
8
Potential and constraints for the application of CFD combined with Lagrangian particle tracking to dry powder inhalers.CFD 结合拉格朗日粒子追踪在干粉吸入器中应用的潜力和限制。
Eur J Pharm Sci. 2019 Feb 1;128:299-324. doi: 10.1016/j.ejps.2018.12.008. Epub 2018 Dec 14.
9
Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients.Turbuhaler®、Breezhaler®和Genuair®干粉吸入气雾剂在慢性阻塞性肺疾病(COPD)患者中,吸入参数、性别、年龄和疾病严重程度对肺部沉积影响的数值模拟
Eur J Pharm Sci. 2020 Nov 1;154:105508. doi: 10.1016/j.ejps.2020.105508. Epub 2020 Aug 21.
10
Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.硬脂酸镁对干粉吸入制剂气溶胶性能的改性机制研究。
J Pharm Sci. 2018 Apr;107(4):984-998. doi: 10.1016/j.xphs.2017.12.006. Epub 2017 Dec 14.

引用本文的文献

1
Carrier-Free Inhalable Dry Microparticles of Celecoxib: Use of the Electrospraying Technique.塞来昔布无载体可吸入干燥微粒:电喷雾技术的应用。
Biomedicines. 2023 Jun 17;11(6):1747. doi: 10.3390/biomedicines11061747.
2
Investigation of potential substandard dry powder inhalers on EU and North African markets - evaluation of the delivered and fine particle doses.欧盟和北非市场上潜在的不合格干粉吸入器调查——递送剂量和细颗粒剂量评估
J Drug Assess. 2022 Sep 28;11(1):20-25. doi: 10.1080/21556660.2022.2125727. eCollection 2022.
3
Rational Development of a Carrier-Free Dry Powder Inhalation Formulation for Respiratory Viral Infections via Quality by Design: A Drug-Drug Cocrystal of Favipiravir and Theophylline.
通过质量源于设计理念合理开发用于呼吸道病毒感染的无载体干粉吸入制剂:法匹拉韦与茶碱的药物-药物共晶
Pharmaceutics. 2022 Jan 27;14(2):300. doi: 10.3390/pharmaceutics14020300.